VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener, who brings more than three decades of international financial leadership experience, will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's extensive background spans global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This appointment comes at a pivotal time for VERAXA, which is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The addition of Willener is likely to have significant implications for VERAXA's growth trajectory. His deep expertise in capital markets and corporate finance will be instrumental as the company seeks to secure funding for its research and development efforts. The biotech industry is capital-intensive, and having a CFO with a strong track record in raising capital and managing large investment portfolios can provide confidence to investors and partners. This move signals VERAXA's commitment to advancing its oncology pipeline and bringing innovative cancer therapies to market.
Willener's experience in M&A also positions him well to evaluate strategic opportunities, whether that involves partnerships, collaborations, or potential acquisitions. As VERAXA continues to develop its BiTAC platform, strategic alliances with larger pharmaceutical companies could be crucial for clinical development and commercialization. His leadership in these areas will be vital for the company to maximize the potential of its technology.
For industry observers, this appointment underscores the importance of strong financial leadership in the biotech sector. It also highlights the ongoing progress of companies like VERAXA that are focused on next-generation antibody-based therapies, which have the potential to improve cancer treatment outcomes. The move may also be seen as a positive signal for the company's future prospects, as it brings in experienced leadership to navigate the complex financial landscape of drug development.
VERAXA's newsroom provides the latest updates and information regarding VRXA, available at http://nnw.fm/VRXA. The full press release can be viewed at https://nnw.fm/jcHOU.
